SI1533292T1 - Dibenzilaminska spojina in njena medicinska uporaba - Google Patents
Dibenzilaminska spojina in njena medicinska uporabaInfo
- Publication number
- SI1533292T1 SI1533292T1 SI200330767T SI200330767T SI1533292T1 SI 1533292 T1 SI1533292 T1 SI 1533292T1 SI 200330767 T SI200330767 T SI 200330767T SI 200330767 T SI200330767 T SI 200330767T SI 1533292 T1 SI1533292 T1 SI 1533292T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alkyl group
- hydrogen atom
- dibenzylamine compound
- halogen atom
- medicinal use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid Fuels And Fuel-Associated Substances (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002255604 | 2002-08-30 | ||
JP2003107161 | 2003-04-10 | ||
PCT/JP2003/011041 WO2004020393A1 (ja) | 2002-08-30 | 2003-08-29 | ジベンジルアミン化合物及びその医薬用途 |
EP03791414A EP1533292B1 (en) | 2002-08-30 | 2003-08-29 | Dibenzylamine compound and medicinal use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1533292T1 true SI1533292T1 (sl) | 2007-08-31 |
Family
ID=31980551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200330767T SI1533292T1 (sl) | 2002-08-30 | 2003-08-29 | Dibenzilaminska spojina in njena medicinska uporaba |
Country Status (25)
Country | Link |
---|---|
US (2) | US7332514B2 (sl) |
EP (2) | EP1533292B1 (sl) |
KR (1) | KR100634195B1 (sl) |
CN (1) | CN1289467C (sl) |
AT (1) | ATE353870T1 (sl) |
AU (1) | AU2003261826B2 (sl) |
BR (1) | BR0306208A (sl) |
CA (1) | CA2464846C (sl) |
CY (1) | CY1106425T1 (sl) |
CZ (1) | CZ2004627A3 (sl) |
DE (1) | DE60311821T2 (sl) |
DK (1) | DK1533292T3 (sl) |
ES (1) | ES2277142T3 (sl) |
HK (1) | HK1077567A1 (sl) |
IL (2) | IL161559A0 (sl) |
MX (1) | MXPA04005350A (sl) |
NO (1) | NO328886B1 (sl) |
NZ (1) | NZ532494A (sl) |
PT (1) | PT1533292E (sl) |
RU (1) | RU2293078C2 (sl) |
SI (1) | SI1533292T1 (sl) |
SK (1) | SK2332004A3 (sl) |
TR (1) | TR200401413T1 (sl) |
WO (1) | WO2004020393A1 (sl) |
ZA (1) | ZA200403137B (sl) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
WO2004020393A1 (ja) * | 2002-08-30 | 2004-03-11 | Japan Tobacco Inc. | ジベンジルアミン化合物及びその医薬用途 |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
MXPA06003357A (es) * | 2003-09-26 | 2006-06-08 | Japan Tobacco Inc | Metodo para inhibir la produccion de lipoproteina remanente. |
AU2008201550B2 (en) * | 2003-09-26 | 2011-02-10 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
JP4587685B2 (ja) * | 2004-03-23 | 2010-11-24 | セントラル硝子株式会社 | 3−ホルミル−5−トリフルオロメチルベンゾニトリル誘導体とその製造方法 |
US20070208003A1 (en) * | 2004-03-26 | 2007-09-06 | Bell Michael G | Compounds and methods for treating dyslipidemia |
CN1942428A (zh) * | 2004-04-13 | 2007-04-04 | 默克公司 | Cetp抑制剂 |
MXPA06014716A (es) | 2004-06-24 | 2007-03-12 | Lilly Co Eli | Compuestos y metodos para el tratamiento de dislipidemia. |
BRPI0514133A (pt) * | 2004-08-05 | 2008-05-27 | Hoffmann La Roche | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i |
CN101443006B (zh) | 2004-12-31 | 2012-10-10 | 雷迪美国治疗股份有限公司 | 作为cetp抑制剂的新颖的苄胺衍生物 |
US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
US8617604B2 (en) | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20100167986A1 (en) * | 2005-09-30 | 2010-07-01 | Amjad Ali | Cholesteryl Ester Transfer Protein Inhibitors |
JP2009512701A (ja) * | 2005-10-19 | 2009-03-26 | メルク エンド カムパニー インコーポレーテッド | Cetp阻害薬 |
AU2006328328B2 (en) * | 2005-12-22 | 2012-08-30 | Takeda Pharmaceutical Company Limited | Solid preparation containing an insulin sensitizer |
EP1981342B1 (en) * | 2005-12-28 | 2016-11-30 | Dr. Reddy's Laboratories Ltd. | Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors |
WO2007073934A1 (en) * | 2005-12-29 | 2007-07-05 | Novartis Ag | Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp) |
UY30117A1 (es) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US7572823B2 (en) | 2006-02-07 | 2009-08-11 | Hoffmann-La Roche Inc. | Heteroaryl carboxamide compounds |
EP1983966B1 (en) | 2006-02-09 | 2013-06-26 | Merck Sharp & Dohme Corp. | Polymer formulations of cetp inhibitors |
US7919506B2 (en) * | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
US8383660B2 (en) * | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
AU2007247385B2 (en) * | 2006-05-10 | 2011-07-14 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
GB0609268D0 (en) * | 2006-05-10 | 2006-06-21 | Novartis Ag | Organic compounds |
MX2008014291A (es) * | 2006-05-11 | 2008-11-18 | Novartis Ag | Derivados de bencilamina como inhibidores de cetp. |
US8022217B2 (en) | 2006-07-31 | 2011-09-20 | Cadila Healthcare Limited | Compounds suitable as modulators of HDL |
KR100821688B1 (ko) | 2006-08-10 | 2008-04-11 | (주)유케이케미팜 | 암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법 |
US7750019B2 (en) * | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
US7659271B2 (en) * | 2007-04-13 | 2010-02-09 | Kowa Company, Ltd. | Pyrimidine compound having dibenzylamine structure and medicament comprising the same |
JP4846769B2 (ja) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP4834699B2 (ja) * | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP5319457B2 (ja) * | 2008-08-25 | 2013-10-16 | 興和株式会社 | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
EP2383253B1 (en) | 2008-11-28 | 2014-03-19 | Kowa Company, Ltd. | Method for manufacturing trans-{4-[(alkyl amino) methyl]cyclohexyl} acetic ester |
AR077208A1 (es) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
BR112014000333A2 (pt) | 2011-07-08 | 2017-02-07 | Novartis Ag | método de tratamento de aterosclerose em sujeitos com triglicerídeo alto |
JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物 |
KR101803866B1 (ko) | 2011-09-27 | 2017-12-04 | 닥터 레디스 레보러터리즈 리미티드 | 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체 |
WO2014192903A1 (ja) | 2013-05-31 | 2014-12-04 | 興和株式会社 | ジベンジルアミン構造を有するピリミジン化合物の新規形態 |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
BR112019001459A2 (pt) | 2016-07-27 | 2019-05-07 | Hartis-Pharma Sa | combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio. |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576830A (en) * | 1966-08-12 | 1971-04-27 | Sumitomo Chemical Co | Amides containing sulfur |
US4064125A (en) | 1976-10-29 | 1977-12-20 | E. R. Squibb And Sons, Inc. | Substituted amides having antiinflammatory activity |
US4623662A (en) * | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
US4473579A (en) * | 1982-01-26 | 1984-09-25 | American Cyanamid Company | Antiatherosclerotic tetrasubstituted ureas and thioureas |
US5446207A (en) | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
CA2189036A1 (en) | 1994-04-29 | 1995-11-09 | Roland E. Dolle | Halomethyl amides as il-1.beta. protease inhibitors |
AU3577995A (en) | 1994-10-04 | 1996-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
US5834514A (en) * | 1995-05-30 | 1998-11-10 | Vertex Pharmaceuticals, Incorporated | Halomethyl amides as IL-1β protease inhibitors |
GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
AU738134B2 (en) | 1997-10-02 | 2001-09-06 | Sankyo Company Limited | Amidocarboxylic acid derivatives |
EP1068178A1 (en) | 1998-03-05 | 2001-01-17 | Agouron Pharmaceuticals, Inc. | NON-PEPTIDE GnRH AGENTS |
SE9802209D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
ATE361273T1 (de) | 1998-09-25 | 2007-05-15 | Monsanto Co | Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins |
JP2002525350A (ja) | 1998-09-25 | 2002-08-13 | モンサント カンパニー | コレステロールエステル輸送タンパク質活性阻害に有効な置換されたn−脂肪族−n−芳香族第三級ヘテロアルキルアミン |
MXPA01011757A (es) | 1999-05-17 | 2002-06-04 | Novo Nordisk As | Antagonistas / agonistas inversos del glucagon. |
UA73307C2 (uk) | 1999-08-05 | 2005-07-15 | Куміаі Кемікал Індастрі Ко., Лтд. | Похідна карбамату і фунгіцид сільськогосподарського/садівницького призначення |
CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
KR100621294B1 (ko) * | 2002-07-03 | 2006-09-06 | 에프. 호프만-라 로슈 아게 | 옥사졸 유도체 및 이의 인슐린 증감제로서의 용도 |
WO2004020393A1 (ja) * | 2002-08-30 | 2004-03-11 | Japan Tobacco Inc. | ジベンジルアミン化合物及びその医薬用途 |
-
2003
- 2003-08-29 WO PCT/JP2003/011041 patent/WO2004020393A1/ja active IP Right Grant
- 2003-08-29 AU AU2003261826A patent/AU2003261826B2/en not_active Ceased
- 2003-08-29 CN CNB038023830A patent/CN1289467C/zh not_active Expired - Fee Related
- 2003-08-29 IL IL16155903A patent/IL161559A0/xx unknown
- 2003-08-29 TR TR2004/01413T patent/TR200401413T1/xx unknown
- 2003-08-29 SK SK233-2004A patent/SK2332004A3/sk not_active Application Discontinuation
- 2003-08-29 EP EP03791414A patent/EP1533292B1/en not_active Expired - Lifetime
- 2003-08-29 RU RU2004119546/04A patent/RU2293078C2/ru not_active IP Right Cessation
- 2003-08-29 NZ NZ532494A patent/NZ532494A/xx not_active IP Right Cessation
- 2003-08-29 ES ES03791414T patent/ES2277142T3/es not_active Expired - Lifetime
- 2003-08-29 KR KR1020047010002A patent/KR100634195B1/ko not_active IP Right Cessation
- 2003-08-29 PT PT03791414T patent/PT1533292E/pt unknown
- 2003-08-29 SI SI200330767T patent/SI1533292T1/sl unknown
- 2003-08-29 DE DE60311821T patent/DE60311821T2/de not_active Expired - Lifetime
- 2003-08-29 AT AT03791414T patent/ATE353870T1/de active
- 2003-08-29 EP EP07003011A patent/EP1829858A3/en not_active Withdrawn
- 2003-08-29 US US10/503,185 patent/US7332514B2/en not_active Expired - Fee Related
- 2003-08-29 DK DK03791414T patent/DK1533292T3/da active
- 2003-08-29 BR BR0306208-2A patent/BR0306208A/pt not_active IP Right Cessation
- 2003-08-29 CA CA2464846A patent/CA2464846C/en not_active Expired - Fee Related
- 2003-08-29 CZ CZ2004627A patent/CZ2004627A3/cs unknown
-
2004
- 2004-04-22 IL IL161559A patent/IL161559A/en not_active IP Right Cessation
- 2004-04-23 ZA ZA2004/03137A patent/ZA200403137B/en unknown
- 2004-06-03 MX MXPA04005350A patent/MXPA04005350A/es active IP Right Grant
- 2004-06-18 NO NO20042584A patent/NO328886B1/no not_active IP Right Cessation
-
2005
- 2005-10-26 HK HK05109494A patent/HK1077567A1/xx not_active IP Right Cessation
-
2007
- 2007-03-30 CY CY20071100447T patent/CY1106425T1/el unknown
- 2007-11-13 US US11/939,359 patent/US7807701B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1077567A1 (en) | Dibenzylamine compound and medicinal use thereof | |
MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
HK1147490A1 (en) | Condensed aminodihydrothiazine derivative | |
BR0315405A (pt) | Compostos inibidores da integrase tricìclica pré-organizados | |
TW200510440A (en) | Novel compounds | |
MY139887A (en) | Tetrahydronaphthyridine derivatives and a process for preparing the same. | |
WO2005095409A3 (en) | Tetrahydroquinoline derivatives and a process for preparing the same | |
EP1724258A4 (en) | HETEROARYLPHENYLUREE DERIVATIVE | |
TW200745034A (en) | New compounds | |
MX2009012283A (es) | Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1. | |
BG100656A (en) | Derivatives of naphthalene, method and intermediate compounds for their preparation | |
TW200619212A (en) | Morpholine derivatives | |
TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
HUT53099A (en) | Process for producing new tetrahydrobenzimidazole derivatives and pharmaceutical compositions comprising such compounds | |
NO930783L (no) | Kondenserte heterocykliske ketonderivater deres fremstilling og anveendelse | |
AU6158486A (en) | Dihydro pyridine derivatives | |
IL160874A0 (en) | 4-imidazolin-2-one derivatives | |
EP1908752A4 (en) | NEW 2-CHINOLO DERIVATIVES | |
EP1219607A4 (en) | INTEGRASE INHIBITORS WITH AN AROMATIC HETEROCYCLUS | |
HUP0303457A2 (hu) | Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk | |
WO2005053702A3 (en) | Anti-inflammatory agents | |
DE60000978T2 (de) | 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose | |
EP1211253A4 (en) | DIHYDROBENZOFURAN TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND AGENTS | |
HUP0201255A2 (hu) | Új pirimidin-4-on-származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyászati készítmények | |
HU9503718D0 (en) | Serotoninergic abeo-ergoline derivatives |